Summary

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [NCT00930553; Coles AJ et al. ECTRIMS 2014 (poster P090)], a follow-up to the phase 3, randomized, head-to-head CARE-MS I study [NCT00530348], has demonstrated the continuing efficacy and safety of subcutaneous alemtuzumab in treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) who were treated for up to 4 years.